| 摘要 |
Disclosed is the use of a therapeutically effective amount of polyclonal IgG in the manufacture of a medicament for the treatment of a mammal with demyelinating peripheral nerve trauma, wherein the medicament is administered locally or systemically, and wherein said therapeutically effective amount promotes myelination of a peripheral nerve cell by a Schwann cell. Also disclosed is the use of a therapeutically effective amount of polyclonal IgG in the manufacture of a medicament for the treatment of a mammal diagnosed with a demyelinating peripheral neuropathy, wherein the demyelinating peripheral neuropathy is selected from a trauma-induced neuropathy, a toxin-induced neuropathy, an inherited neuropathy, with the proviso that said neuropathy is not an immune-mediated or infection-mediated neuropathy and excludes Guillain-Barré syndrome, chronic demyelinating polyneuropathy and multifocal motor neuropathy, wherein the IgG is administered locally or systemically, and wherein said therapeutically effective amount promotes myelination of a peripheral nerve cell by a Schwann cell. |
